Bausch + Lomb BLCO · NYSE
$20.01 +0.03% (+$0.01)
Summary
57 / 100 · Bulios Score
What speaks for it
- It earns 97 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $513.0M against $45.0M.
- Revenue grew by 11% a year over the last 3 years.
What to watch
- The company made a loss over the last 12 months.
- Operating profit does not even cover the interest on its debt.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 8.4% a year over 5 years. Over the last 3 years it grew by 11% a year. For the next fiscal year analysts expect revenue to grow by 7.8%.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $111.0M.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 8
- Hold 8
- Sell 1
Today's price within the analysts' price targets
The average target of $20.83 is 4.1% above today's price. 47% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Device Products 38%
- Over the Counter Products 36%
- Pharmaceutical Products 21%
- Branded and Other Generic Products 4.8%
- Other Revenues 0.4%
By region
- United States and Puerto Rico 53%
- Other Countries 16%
- CHINA 7.4%
- FRANCE 5.1%
- JAPAN 3.9%
- Other 15%
Device Products brings in 38% of revenue. Pharmaceutical Products grew fastest, by 32% a year.
Segments in detail